One of Korea's oldest and largest pharmaceutical companies, known for lung-cancer drug lazertinib and consumer health products.
One of Korea's oldest and largest pharmaceutical companies, known for lung-cancer drug lazertinib and consumer health products.
Sells prescription drugs, many in-licensed from foreign makers and distributed in Korea, and earns milestone payments and royalties from Janssen on lazertinib, the lung-cancer drug it discovered and licensed out in 2018. Yuhan-Kimberly, a joint venture with Kimberly-Clark making tissue and hygiene products, adds income through its stake.
Moat: narrow (IP / patents, brand). Lazertinib is a globally licensed, approved lung-cancer drug, unusual for a Korean pharma.
Headquarters: Seoul, South Korea · Founded: 1926 · Employees: 2,153
Size Yuhan (000100.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $4.11B, the 88th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩80,100 on 18 Nov 2026.
Performance Over six months the shares fell 10.4%, against +0.8% for the median peer and -37.2% for the South Korea market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +3.0%); the operating margin is 5.9% (peer median 19.2%).
Valuation It trades at 40.4× forward earnings against a peer median of 18.5× (2nd most expensive of 15).
Capital Return on invested capital runs 1.4 points below its cost of capital (5.5% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩2.32T | ₩2.19T | ₩2.07T | ₩1.86T | ₩1.78T |
| Revenue growth | — | +6% | +11% | +5% | — |
| Gross profit | ₩814B | ₩728B | ₩706B | ₩596B | ₩544B |
| EBITDA | ₩216B | ₩174B | ₩118B | ₩101B | ₩79.0B |
| Net income | ₩232B | ₩194B | ₩70.7B | ₩136B | ₩95.1B |
| Free cash flow | -₩10.9B | -₩3.63B | -₩62.5B | -₩17.4B | ₩41.2B |
| Capital expenditure | ₩191B | ₩145B | ₩134B | ₩204B | ₩94.4B |
| Total debt | ₩338B | ₩343B | ₩305B | ₩230B | ₩97.7B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Yuhan 000100.KS | $4.11B | -10% | +8% | 6% | 40.4× | n/a |
| HanmiPharm 128940.KS | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Daewoong Pharm 069620.KS | $856M | -33% | +9% | 12% | 9.0× | n/a |
| Chongkundang 185750.KS | $609M | -27% | +6% | 4% | 11.4× | -6.6% |
| JW Pharmaceutical 001060.KS | $423M | -26% | +9% | 13% | 6.3× | -15.4% |
| GC Biopharma 006280.KS | $1.12B | -10% | -3% | 4% | 4.6× | n/a |
| Boryung 003850.KS | $554M | -13% | +6% | 6% | 11.3× | -3.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000100.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.1% | +0.2% | 6th lowest of 21 |
| 6-month return | -10.4% | +0.8% | 6th lowest of 20 |
| Distance from 52-week high | -37.7% | -26.4% | 7th lowest of 21 |
| Revenue growth (TTM) | +8.4% | +3.0% | 8th highest of 19 |
| Operating margin | 5.9% | 19.2% | 5th lowest of 18 |
| Forward P/E | 40.4× | 18.5× | 2nd most expensive of 15 |
| ROIC minus cost of capital | -1.4 pp | +6.9 pp | 3rd lowest of 18 |
| EV / EBITDA | 25.3× | 16.1× | 3rd most expensive of 9 |
| Net debt / EBITDA | -0.5× | -0.1× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |
| Santen Pharmaceutical 4536.T | Japan | $4.14B | +10% | +2% | 16% | 16.7× | -5.0% | +3.2% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | China | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% | +9.7% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| Guangzhou Baiyunshan Pharmaceutical 600332.SS | China | $4.45B | -13% | +1% | 3% | 12.9× | -0.7% | +4.7% |
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |